320 related articles for article (PubMed ID: 31470935)
1. From Bench to Bedside-The Bad Berka Experience With First-in-Human Studies.
Zhang J; Singh A; Kulkarni HR; Schuchardt C; Müller D; Wester HJ; Maina T; Rösch F; van der Meulen NP; Müller C; Mäcke H; Baum RP
Semin Nucl Med; 2019 Sep; 49(5):422-437. PubMed ID: 31470935
[TBL] [Abstract][Full Text] [Related]
2. Radiopharmaceuticals for the Diagnosis and Therapy of Neuroendocrine Differentiated Prostate Cancer.
Giovacchini G; Giovannini E; Riondato M; Ciarmiello A
Curr Radiopharm; 2017; 10(1):6-15. PubMed ID: 28034291
[TBL] [Abstract][Full Text] [Related]
3. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
4. Bioconjugates of Chelators with Peptides and Proteins in Nuclear Medicine: Historical Importance, Current Innovations, and Future Challenges.
Jackson JA; Hungnes IN; Ma MT; Rivas C
Bioconjug Chem; 2020 Mar; 31(3):483-491. PubMed ID: 31990543
[TBL] [Abstract][Full Text] [Related]
5. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
[TBL] [Abstract][Full Text] [Related]
6. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides.
Morgan KA; Rudd SE; Noor A; Donnelly PS
Chem Rev; 2023 Oct; 123(20):12004-12035. PubMed ID: 37796539
[TBL] [Abstract][Full Text] [Related]
7. THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience.
Baum RP; Kulkarni HR
Theranostics; 2012; 2(5):437-47. PubMed ID: 22768024
[TBL] [Abstract][Full Text] [Related]
8. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
Béhé M; Behr TM
Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
[TBL] [Abstract][Full Text] [Related]
9. Clinical Translation and First In-Human Use of [
Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
[TBL] [Abstract][Full Text] [Related]
10. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
11. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
Langbein T; Weber WA; Eiber M
J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
[TBL] [Abstract][Full Text] [Related]
12. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Van Laere C; Koole M; Deroose CM; de Voorde MV; Baete K; Cocolios TE; Duchemin C; Ooms M; Cleeren F
Theranostics; 2024; 14(4):1720-1743. PubMed ID: 38389843
[TBL] [Abstract][Full Text] [Related]
13. Radiopeptide imaging and therapy in Europe.
Ambrosini V; Fani M; Fanti S; Forrer F; Maecke HR
J Nucl Med; 2011 Dec; 52 Suppl 2():42S-55S. PubMed ID: 22144555
[TBL] [Abstract][Full Text] [Related]
14. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
15. Radiolabeled peptides in oncology: role in diagnosis and treatment.
Weiner RE; Thakur ML
BioDrugs; 2005; 19(3):145-63. PubMed ID: 15984900
[TBL] [Abstract][Full Text] [Related]
16. Theranostic approaches in nuclear medicine: current status and future prospects.
Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
[No Abstract] [Full Text] [Related]
17. Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.
Baum RP; Kulkarni HR; Carreras C
Semin Nucl Med; 2012 May; 42(3):190-207. PubMed ID: 22475428
[TBL] [Abstract][Full Text] [Related]
18. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
19. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013.
Kulkarni HR; Singh A; Schuchardt C; Niepsch K; Sayeg M; Leshch Y; Wester HJ; Baum RP
J Nucl Med; 2016 Oct; 57(Suppl 3):97S-104S. PubMed ID: 27694180
[TBL] [Abstract][Full Text] [Related]
20. Bench-to-Bedside Theranostics in Nuclear Medicine.
Jokar N; Assadi M; Yordanova A; Ahmadzadehfar H
Curr Pharm Des; 2020; 26(31):3804-3811. PubMed ID: 32067609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
